Our Pipeline
Anebulo at a Glance
We are a clinical stage biotech company developing novel solutions to help people suffering from acute cannabinoid toxicity. Our lead product candidate is an antidote to treat acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning.
ANEB-001 Cannibinoid Intoxication
Phase 2
Anebulo aims to leverage distinct formulations/combinations of the same API to develop 3 distinct products to help patients suffering from acute cannabis toxicities. This will allow the company to rapidly advance to proof-of-concept trials.
ANEB-001PHASE 2
ANEB-001 has established Phase 2 proof of concept where the final data has shown favorable tolerability and efficacy data of ANEB-001 in rapidly reversing the effects in our THC challenge study. ANEB-001is a competitive CB1 antagonist with a high affinity for the human CB1 receptor. There is currently no medical treatment approved to alleviate the symptoms of cannabinoid intoxication.
ANEB-001 is a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for cannabinoid intoxication. We believe ANEB-001 will reverse the symptoms of acute cannabinoid toxicities based on our Phase 2 studies.
